NorthWest Biotherapeutics Inc (NWBO)

[MI Dendream]

Hi Senti, I was actually referring to the LBI news. My guess is that when their study design comes out it too will be a hybrid design following the path of a recent competitor. To me this says two important things.

One is very good in that a second new GBM trial with a hybrid contemporaneous cohort design, hopefully with a better randomization scheme than 3:1. Something like 6:1 still gives a patient a 15% chance of nothingburger, but compromise is compromise and you can’t get it all when you compromise. This shows FDA has bought into hybrid cohort designs.

The other is not as good in that, maybe the reason for the hybrid moving forward in rGBM, especially a hybrid that only improves 2:1 up to 3:1 tells me that the faith in the rGBM contemporaneous control population is not super strong yet. Perhaps, the first secondary is the reason for the mulling and tinkering. It is not a large group on either side of the blind and the synthetic cohort has some swag to it. Looks to me like FDA may not be convinced it is the new SOC for rGBM and is allowing companies to compete in a similar fashion. This will help add new patients to the synthetic pool moving forward as well.

The fact that these are rGBM and not ndGBM is a very good sign to me. Very, very good. Very, very, very good.

I honestly don’t think the counter spin adds up to bad news if one uses logic.